Surprisingly, we found that overexpression of MYC with oncogenes other than MET did not produce a striking change in the expression of genes switched in Myc-R26Met versus Alb-R26Met tumours (Afp, Spp1, Gpc3, Epcam, Mki67, Hgma1, Csp1 (Hep-Par1), Vim, Cdh1 markers, and Ctla4, Lag3, Icosl immune checkpoints; Fig. 5D). The gene discussed is EPCAM; the disease is neoplasm.